Eterna Therapeutics Inc (ERNA)
$1.9
Insights on Eterna Therapeutics Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 72.6% return, outperforming this stock by 77.6%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 323.4%
Performance
- $1.81$2.22$1.90
4.64%
Downside
Day's Volatility :18.38%
Upside
14.41%
- $0.84$2.99$1.90
55.78%
Downside
52 Weeks Volatility :71.9%
Upside
36.45%
Returns
| Period | Eterna Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 3.75% | 0.0% |
6 Months | 57.02% | 0.0% |
1 Year | -4.52% | 0.0% |
3 Years | -88.31% | -22.6% |
Highlights
Market Capitalization | 10.3M |
Book Value | $0.41 |
Earnings Per Share (EPS) | -4.45 |
Wall Street Target Price | 3.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -33911.77% |
Return On Assets TTM | -36.19% |
Return On Equity TTM | -302.2% |
Revenue TTM | 68.0K |
Revenue Per Share TTM | 0.01 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -20.6M |
Diluted Eps TTM | -4.45 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 57.89%
Technicals Summary
Sell
Neutral
Buy
Eterna Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Eterna Therapeutics Inc | 7.95% | 57.02% | -4.52% | -88.31% | -71.98% |
 Moderna, Inc. | 21.03% | 85.08% | 14.68% | -28.27% | 659.22% |
 Regeneron Pharmaceuticals, Inc. | 3.22% | 20.18% | 31.88% | 93.3% | 227.58% |
 Novo Nordisk A/s | 8.85% | 34.38% | 71.83% | 235.07% | 463.44% |
 Vertex Pharmaceuticals Incorporated | 16.81% | 34.1% | 40.6% | 123.97% | 174.53% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Eterna Therapeutics Inc | NA | NA | NA | 0.0 | -3.02 | -0.36 | NA | 0.41 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.14 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.89 | 28.89 | 1.46 | 44.13 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.97 | 46.97 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 29.59 | 29.59 | 0.53 | 17.08 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Eterna Therapeutics Inc | Sell | $10.3M | -71.98% | NA | 0.0% |
Moderna, Inc. | Buy | $54.6B | 659.22% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.0B | 227.58% | 28.89 | 29.45% |
Novo Nordisk A/s | Buy | $602.6B | 463.44% | 46.97 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 174.53% | 29.59 | 39.46% |
Institutional Holdings
LAKE STREET ADVISORS GROUP, LLC
9.63%Cypress Point Wealth Management, LLC
1.74%Naviter Wealth, LLC
1.46%Sippican Capital Adivsors
1.35%CI Private Wealth LLC
0.93%Vanguard Group Inc
0.48%
Company Information
brooklyn is focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases. brooklyn’s most advanced program is irx-2, a human cell-derived cytokine therapy, studying the safety and efficacy of irx-2 in patients with head and neck cancer in phase 2b. in a phase 2a clinical trial in head and neck cancer, irx-2 demonstrated an overall survival benefit. additional studies are either underway or planned in other solid tumor cancer indications. brooklyn has multiple next-generation cell and gene-editing therapies in preclinical development for various indications including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. for more information about brooklyn and its clinical programs, please visit www.brooklynitx.com.
Organization | Eterna Therapeutics Inc |
Employees | 8 |
CEO | Ms. Sandra M. Gurrola |
Industry | Healthcare |
